The complement protein C3 is a common denominator in the activation of the classical, alternative, and lectin pathways of the complement system. In addition, its interactions with several cell-surface receptors make it a key participant in phagocytic and immunoregulatory processes, while its interactions with proteins from foreign pathogens may provide a mechanism by which these microorganisms evade complement neutralization. To date, C3 is known to interact with at least 25 different proteins, including serum proteins, cell surface receptors and proteins of foreign origin. Elucidation of the molecular features related to these C3 associated interactions still requires further analysis of the C3 protein. The long-term goal of this proposal is to identify the structural determinants associated with various functions of this important macromolecule. The proposed study will involve a detailed structural and functional analysis of the interactions between the human C3 fragments C3(H2O), C3b, iC3b, C3c and C3dg, and the complement regulatory proteins, factor H and complement receptor type one (CR1) and to compare these interactions to those of the viral complement regulatory proteins VCP and SPICE with the same C3 fragments. Protein expression, isothermal titration calorimetry (ITC), and hydrogen exchange/mass spectrometry (HDX-MS) will be used to assess the molecular forces that impart specificity and recognition to the interactions between the host complement components and the host and viral regulatory proteins. The functional sites of the interacting molecules will be mapped using HDX-MS, computational methods, and site-directed mutagenesis. The proposed studies are designed to provide basic information on the structural features of C3-ligand interactions as they relate to complement functions. These studies should provide insight into how the virus's complement regulatory molecules help the virus evade complement attack and also assist in the design of specific inhibitors that may have important medical applications. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI030040-11A1
Application #
7147769
Study Section
Special Emphasis Panel (ZRG1-III-F (01))
Program Officer
Sawyer, Richard T
Project Start
1992-12-01
Project End
2011-05-31
Budget Start
2006-06-15
Budget End
2007-05-31
Support Year
11
Fiscal Year
2006
Total Cost
$326,375
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Mastellos, Dimitrios C; Reis, Edimara S; Yancopoulou, Despina et al. (2018) Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol 55:167-175
Reis, Edimara S; Mastellos, Dimitrios C; Ricklin, Daniel et al. (2018) Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18:5-18
Huber-Lang, Markus; Lambris, John D; Ward, Peter A (2018) Innate immune responses to trauma. Nat Immunol 19:327-341
Ricklin, Daniel; Mastellos, Dimitrios C; Reis, Edimara S et al. (2018) The renaissance of complement therapeutics. Nat Rev Nephrol 14:26-47
Wang, HongBin; Ricklin, Daniel; Lambris, John D (2017) Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci U S A 114:10948-10953
Wolf-Grosse, Susann; Rokstad, Anne Mari; Ali, Syed et al. (2017) Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. Int J Nanomedicine 12:3927-3940
Hajishengallis, G; Krauss, J L; Jotwani, R et al. (2017) Differential capacity for complement receptor-mediated immune evasion by Porphyromonas gingivalis depending on the type of innate leukocyte. Mol Oral Microbiol 32:154-165
Gravastrand, Caroline; Hamad, Shamal; Fure, Hilde et al. (2017) Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. Acta Biomater 58:158-167
Kajikawa, Tetsuhiro; Briones, Ruel A; Resuello, Ranillo R G et al. (2017) Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev 6:207-215
Harder, Markus J; Kuhn, Nadine; Schrezenmeier, Hubert et al. (2017) Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood 129:970-980

Showing the most recent 10 out of 174 publications